First Oral Prophylaxis for Hereditary Angioedema: Insights from Clinical and Real-World Evidence - European Medical Journal

First Oral Prophylaxis for Hereditary Angioedema: Insights from Clinical and Real-World Evidence

Allergy & Immunology

This educational webinar is aimed at healthcare professionals and has been organised and funded by BioCryst Pharmaceuticals.

Disclaimer: Prescribing information for BioCryst products mentioned in this article: Orladeyo (berotralstat) can be found here. Always consult local prescribing information in country of practice as information may vary.

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: or search for MHRA Yellow Card in the Google Play or Apple App Store. For non-UK HCPs, suspected adverse reactions should be reported via national reporting system in country of practice.


Discover the latest advancements in hereditary angioedema (HAE) treatment with our exclusive webinar, moderated by Hannah Moir and featuring renowned expert Sorena Kiani, Consultant Immunologist, Royal Free Hospital, London, UK.

Delve into a comprehensive overview of angioedema types and the pathophysiology of bradykinin-mediated angioedema. Explore current treatment options targeting HAE mechanisms, with a focus on the first oral prophylaxis, berotralstat. Gain valuable insights into berotralstat’s efficacy and safety in adults and adolescents aged 12 and older.

During the question-and-answer session, Kiani and Moir will explore topics such as the impact of HAE aetiology on treatment selection, criteria for oral prophylactic therapy, lifestyle adjustments, patient adherence concerns, and considerations for specific situations.

Sorena Kiani
Sorena Kiani, Consultant Immunologist, Royal Free Hospital, London, earned his medical degree from University College London, UK, and a PhD in immunology. He specialised in clinical immunology at King’s College Hospital, London, UK, worked as a consultant immunologist at Royal Surrey and Barts Health, Guildford, UK, and later joined the Royal Free Hospital. Recognised by the European Academy of Allergy and Clinical Immunology (EAACI) in 2010, he developed an innovative desensitization method for anaphylaxis-causing proteins. Kiani, with expertise in Allergy and Clinical Immunology at King’s College London, addresses the rising public interest in allergies.

UK.BCX.00291 Date of preparation: March, 2024

Please rate the quality of this content

As you found this content interesting...

Follow us on social media!

We are sorry that this content was not interesting for you!

Let us improve this content!

Tell us how we can improve this content?